AbbVie's (NYSE: ABBV) earnings and revenue for the second quarter of 2019 surpassed Wall Street's estimates. AbbVie reported adjusted EPS of $2.26
AbbVie tops Q2 views; lifts FY19 earnings outlook
Categories
Health Care
Bristol-Myers Q2 earnings, revenue top Street; stock dips on weak guidance
Biopharma company Bristol-Myers Squibb (NYSE: BMY) on Thursday reported higher earnings and revenues for the second quarter, The results also came in
AstraZeneca’s Q2 results beat market expectations
AstraZeneca Plc (NYSE: AZN) topped market estimates for revenue and earnings in the second quarter of 2019, giving shares a lift of
What to expect from AbbVie Q2 earnings
AbbVie (NYSE: ABBV) is scheduled to report its earnings results for the second quarter of 2019 on Friday before the market opens.
Earnings preview: Celgene deal in focus as Bristol-Myers prepares for Q2 results
Bristol-Myers Squibb (NYSE: BMY) will be releasing its quarterly results amid growing skepticism over the planned acquisition of rival drugmaker Celgene (CELG),
Boston Scientific Q2 profit dips 72% but beats estimates
Boston Scientific Corporation (NYSE: BSX) reported a 72% dip in earnings for the second quarter due to higher costs and expenses as well
Earnings: Alexion Pharma Q2 results top expectations; raises FY19 guidance
Alexion Pharmaceuticals (Nasdaq: ALXN) reported a 28% growth for its second-quarter earnings, helped by an increase in revenues. The results also topped
Edwards Lifesciences stock surges on Q2 earnings beat, raises 2019 outlook
Edwards Lifesciences (NYSE: EW) stock price increased 10% in the after-market trading as the second-quarter results surpassed estimates. In addition, the company
Aethlon Medical earnings preview: Cash crunch at its peak ahead of Q4 results
Aethlon Medical (NASDAQ: AEMD) is trading near an all-time low as it heads towards its fourth-quarter financial results, slated for Monday, July
Pfizer secures FDA approval for oncology biosimilar Zirabev; stock gains
A day after appointing former FDA chief Scott Gottlieb to its board of directors, pharma giant Pfizer (PFE) said it received FDA
What the future holds for generic drug industry
The size of the generic drug market in the US is so large that about 90% of all prescription medicines sold last
M&A alert: AbbVie agrees to acquire Allergan for $63 billion
Confirming reports published by Wall Street Journal earlier today, pharmaceutical giant Abbvie (NYSE: ABBV) said it would acquire Irish competitor Allergan (NYSE:
Bristol-Myers lets go of psoriasis drug to save Celgene merger; stock falls
The planned merger between pharmaceutical firms Bristol-Myers Squibb Company (NYSE: BMY) and Celgene (CELG) - touted as a landmark deal in the
DEEP FOCUS: Everything you need to know about GW Pharmaceuticals
Shares of GW Pharmaceuticals (NASDAQ: GWPH) have gained 72% in the year-to-date period, emerging as a new favorite among pot investors. However,
Ocular Therapeutix gains after FDA approves eye drug for additional indication
Ocular Therapeutix (Nasdaq: OCUL) staged a dramatic recovery Friday after receiving the FDA’s green signal for its ophthalmic drug DEXTENZA to include
Chevron Phillips Chemical is looking to acquire Nova Chemicals
Chevron Phillips Chemical Company, a joint venture between Chevron Corp. (NYSE: CVX) and Phillips 66 (NYSE: PSX) is reportedly looking to acquire
Earnings: Canopy Growth posts big Q4 miss, but investors remain stoic
Canopy Growth (NYSE: CGC) reported a loss of CAD 0.98 per share on revenues of CAD 94.1 million in the fourth quarter,
MediWound stock plunges to a record low on gloomy future
MediWound Ltd. (NASDAQ: MDWD) stock plunged to a record low of $3.52 on Tuesday. The future of the biopharmaceutical company looks gloomy
Pharma stocks: Merck is on a buying spree
Several merger and acquisition deals are being announced in the healthcare sector, the most recent one being the acquisition of Array Biopharma
Earnings preview: Will Canopy Growth post upbeat Q4 2019 results?
Canopy Growth (TSX: WEED, NYSE: CGC) is scheduled to release its financial results for the fourth fiscal quarter of 2019 after the
Pfizer boosts oncology portfolio with $10-Bil acquisition of Array Biopharma
In a sign that the consolidation wave that swept in the pharmaceutical industry last year is likely to continue, Pfizer (NYSE: PFE)